Anteotech Ltd · ASX:ADO
Anteotech — Anteo Diagnostics — Shareholder Meeting (November 2018)
27 slides from Anteotech's shareholder meeting presentation, Nov 16, 2018
Slide 1: Chairman's Address and Presentation to Anteo AGM
Chairman’s Address and Presentation to Anteo AGM ASX Release 16 November 2018 For personal use only Good morning everyone, my name is Jack Hamilton and I am the Chair of the Anteo Diagnostics Limited (“Anteo” or the “Company”) Board. I would like to welcome you all to Anteo’s 2018 Annual General Mee
Slide 2: Chairman's address: battery and Point of Care strategy
The strategy to pursue the Battery and Point of Care sectors are driven by market fundamentals. The rapid electrification of our lives is seeing increasing power demand needs in batteries particularly Lithium ion batteries where the initial results For personal use only of Anteo technology is giving
Slide 3: Chairman's address: Point of Care and about Anteo
developing markets such as China where PoC is rapidly expanding both as an end market but also a manufacturing centre. Since generating the internal work released in August plus some follow up work that Chris will share with you, we have added For personal use only 18 active new PoC commercial leads
Slide 4: Annual General Meeting November 2018
For personal use only Annual General Meeting November 2018 Dr Jack Hamilton (Chair) Mr Christopher Parker (CEO)
Slide 5: Disclaimer
Disclaimer For personal use only The purpose of the presentation is to provide an update of the business of Anteo Diagnostics Ltd (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly,
Slide 6: Agenda
Agenda For personal use only • Anteo’s Strategy and Focus Areas • Batteries • Point of Care • Summary
Slide 7: Anteo's Strategy & Focus Areas
For personal use only Anteo’s Strategy & Focus Areas
Slide 8: Strategy and Focus Areas
Strategy and Focus Areas For personal use only The Board has re-visited the purpose and strategy outlined last November and 1 has narrowed the focus of exploiting the company’s IP to the potential AnteoCoatTM offers in the battery market and to the superior conjugation properties of AnteoBindTM in t
Slide 9: Anteo's markets, opportunities, and focus areas
Anteo’s markets, opportunities, and focus areas For personal use only ANTEO FOCUS AREAS In Vitro & Life Energy Point of Care MedTech Science Diagnostics – AnteoCoat - AnteoBind - AnteoRelease - AnteoBind $6bn market >$2.5bn market $2bn market >$30bn market Si Anodes Orthopedic Infectious diseases Ac
Slide 10: Funnel of Opportunities
Funnel of Opportunities For personal use only MEDTECH • Progress has been made on CARDIOLOGY driving our key focus areas down DRUG ELUTING BATTERY ANODE the commercialisation pathway STENTS ENHANCEMENT SILICON BATTERY ANODE COMPOSITES ENHANCEMENT • Battery focus is on demonstrating SURFACE AnteoCoat
Slide 11: Batteries
For personal use only Batteries
Slide 12: Foundation Results Informing Strategic Focus
Foundation Results Informing Strategic Focus For personal use only • Foundation results created by Polaris Battery Labs informed Anteo’s approach to silicon anodes • Anteo’s surface modified silicon improved the integration of the silicon with the graphite anode structure under test conditions used
Slide 13: Strategic Project Focus
Strategic Project Focus For personal use only SURFACE MODIFIED SILICON • Offers a nearer term commercialisation opportunity • Approach targets low to medium silicon content anodes • Development targets confirmed with industry and scheduled Silicon composites work will be carried out in close collabo
Slide 14: Surface Modified Silicon
Surface Modified Silicon For personal use only ANTEO • Anteo received strong interest in surface modified silicon from global manufacturers of battery materials • Several Information exchanges with external parties Silicon Surface modified silicon resulted in two high quality collaborations • Work o
Slide 15: Silicon Composites
Silicon Composites For personal use only Silicon ANTEO • Anteo made substantial progress in the processing of silicon composites over the past months Carbon Silicon/carbon composite • A key achievement was the development of processing parameters that allow for improved control over the particle Ima
Slide 16: Development Focus – Timeline (18 months)
Development Focus – Timeline (18 months) For personal use only SURFACE MODIFIED SILICON PRODUCT OPPORTUNITY Collaborator 1: Feasibility study Extended R&D plan Internal/External Joint material development Joint product commercialisation Collaborator 2: R&D plan Internal development work Evaluation b
Slide 17: Next Steps
Next Steps For personal use only ACHIEVEMENTS AND OUTCOMES TO DATE • Identified industry partners to seek involvement in next stages of development work 1 • Confirmed interest in a surface modified silicon product • Signed Materials Transfer Agreement and agreed on scope of feasibility study with a
Slide 18: Point of Care
For personal use only Point of Care
Slide 19: PoC Market and Role for AnteoBind
PoC Market and Role for AnteoBind™ For personal use only LFIA market Further confirmation of AnteoBind™ opportunities in quantitative lateral flow USD $Billions assays at Merck IVD conference & Advanced Lateral Flow Conference in Oct • The Lateral Flow Immunoassay (LFIA) segment continues to grow st
Slide 20: AnteoBind - Advantages and Messaging
AnteoBind™ - Advantages and Messaging For personal use only Functional Nanocoating : Antibody • Simple to use • Addition of AnteoBind™ solution and wash off the excess Reproducible procedure batch-to-batch • Proteins Nanoparticles • Stable surfaces or polymers • Activated-particles can be stored saf
Slide 21: AnteoBind cTnI Europium Assay Results
AnteoBind™ cTnI Europium Assay Results: “Real World”Conjugate Performance Demonstrated For personal use only • Anteo achieved excellent outcomes in the transition from prototype results to “real world” cTnI Lateral Flow Assay in Serum 900 Relative Fluorescence Units (mV) serum-based system. 800 • An
Slide 22: Anteo POC Business Model Focus
Anteo POC Business Model Focus For personal use only POCT VALUE CHAIN Research POCT LFIA Particle Assay or Reader Anteo own brand LFIA IVD companies companies companies companies Develop full POCT High value, High value, High value, assays - ISO13485 high competition high competition high competitio
Slide 23: Anteo POC Business Model Focus: Current Opportunities
Anteo POC Business Model Focus Current Opportunities For personal use only POCT VALUE CHAIN Research POCT LFIA Particle Assay or Reader And Anteo own brand LFIA IVD companies companies companies companies Develop full POCT High value, High value, High value, assays - ISO13485 high competition high c
Slide 24: Point of Care next steps
Point of Care next steps For personal use only ONGOING ACTIONS AND BUSINESS FOCUS • Capitalise on positive interest and numerous customer leads from Business 1 Development activities at the Merck IVD conference and Advance Lateral Flow Course Anteo attended in October • Revitalise large geographic m
Slide 25: Summary
For personal use only Summary
Slide 26: Anteo Focus in Summary
Anteo Focus in Summary For personal use only BATTERY PARTNERSHIPS ANTEOBIND MESSAGING Complete work plans with collaborators and Continue to communicate AnteoBind™ continue to define opportunities for joint messaging of superior conjugation material development and commercialisation performance and
Slide 27: For more information contact
For more information contact For personal use only Mr Christopher Parker CEO chris.parker@anteodx.com Dr Jack Hamilton Chair jack.hamilton@anteodx.com Mr Julien McInally Company Sec. julien.mcinally@anteodx.com anteotech.com ASX:ADO
Anteo Diagnostics — Shareholder Meeting (November 2018) on 6ix